Cardiff Oncology Inc. (CRDF)
NASDAQ: CRDF
· Real-Time Price · USD
3.81
-0.05 (-1.30%)
At close: Jun 17, 2025, 10:30 AM
-1.30% (1D)
| Bid | 3.8 |
| Market Cap | 253.46M |
| Revenue (ttm) | 479K |
| Net Income (ttm) | -48.86M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -4.1 |
| Forward PE | -3.93 |
| Analyst | Buy |
| Ask | 3.81 |
| Volume | 187,139 |
| Avg. Volume (20D) | 1,157,071 |
| Open | 3.84 |
| Previous Close | 3.86 |
| Day's Range | 3.72 - 3.85 |
| 52-Week Range | 2.01 - 5.64 |
| Beta | 1.56 |
About CRDF
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRDF
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRDF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+19.88%
Cardiff Oncology shares are trading higher after P...
Unlock content with
Pro Subscription
6 months ago
+54.92%
Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.
